Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 27

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 27
---
ger Agreement”) as announced and filed with the United States Securities and Exchange Commission on November 4 and 5, 2024. Proposal:The Board of Directors proposes that the Merger Agreement be approved on an advisory basis. 2. Par Value Reduction, Reverse Split and Contribution in Kind Explanation:As per the Merger Agreement, (i) NLS Pharmaceutics (Israel) Ltd., an Israeli company and a wholly owned subsidiary of the Company, is intended to merge with and into Kadimastem, with Kadimastem as the surviving company (the “ Merger”), and (ii) at the effective time of the Merger (the “Effective Time”), each issued and outstanding ordinary share of Kadimastem, with no par value (each, a “ Kadimastem Ordinary Share”), is expected to be exchanged for and automatically converted into the right to receive from the Company that certain number of fully paid in registered common shares of the Company, 0.03 Swiss Franc (CHF) par value per share (which par value is subject to amendment as a result of a par value reduction and reverse split to be resolved at the NLS Meeting) (the “ NLS Common Shares”), as calculated pursuant to a formula and in accordance with the terms of the Merger Agreement (the “ Exchange Ratio”). According to Israeli law, the Merger leads to the contribution of the Kadimastem Ordinary Shares to the Company by operation of law. Therefore, in order to effect the transactions contemplated by the Merger Agreement, the Company’s share capital requires an increase and the new NLS Common Shares shall be issued against the contribution of the Kadimastem Ordinary Shares. The number of NLS Common Shares to be issued is not yet known because the Merger Agreement provides for a mechanism to adjust the Exchange Ratio.

As a preparatory measure in connection with the Merger and in order to increase the par value per NLS Common Share, 0.03 Swiss Franc (CHF) par value per share, preferred share of the Company, 0.03 Swiss Franc (CHF) par value per share (“Preferred Share”) and PPC of the Company, 0.03 Swiss Franc (CHF) par value per certificate (“ PPC”), and, ceteris paribus, the market price per share of the NLS Common Share on the Nasdaq, the Board of Directors proposes a reverse stock split (consolidation of the NLS Common Shares, Preferred Shares and PPCs) with a ratio to